{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:38:12Z","timestamp":1777934292924,"version":"3.51.4"},"reference-count":31,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T00:00:00Z","timestamp":1507680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:p>There exists little guidance on chemotherapy toxicity management in patients with a history of or active hepatitis C viral infection. We report four cases of patients with solid organ tumors and hepatitis C viral infection, who have experienced severe or unexpected toxicities with chemotherapy. Based on the four case reports, we recommend increased laboratory monitoring for toxicities, initial dose reductions for chemotherapy given with palliative intent, or pre-emptive use of growth factor support, even if the patient presents with normal liver function tests. In this patient population, we also recommend treating active hepatitis C viral infection prior to chemotherapy treatment when possible.<\/jats:p>","DOI":"10.1177\/1078155217734626","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T00:52:25Z","timestamp":1507769545000},"page":"474-480","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Hepatitis C infection and chemotherapy toxicity"],"prefix":"10.1177","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2801-2092","authenticated-orcid":false,"given":"Amy","family":"Ly","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Washington Medicine\/Seattle Cancer Care Alliance, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather H","family":"Cheng","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, University of Washington, Seattle, WA, USA"},{"name":"Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Alwan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Washington Medicine\/Seattle Cancer Care Alliance, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,10,11]]},"reference":[{"key":"bibr1-1078155217734626","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i11.2771"},{"key":"bibr2-1078155217734626","unstructured":"National Comprehensive Cancer Network. Prevention and treatment of cancer-related infections (Version 2.2017). Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ infections.pdf (accessed 7 August 2017)."},{"key":"bibr3-1078155217734626","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2013.001215"},{"key":"bibr4-1078155217734626","unstructured":"Advances in medications to treat hepatitis C. American Liver Foundation. Available at: Hepc.liverfoundation.org (2016, accessed 1 May 2017)."},{"key":"bibr5-1078155217734626","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.15.157784"},{"key":"bibr6-1078155217734626","unstructured":"\u201cMonitoring patients who are starting hepatitis C treatment, are on treatment, or have completed therapy.\u201d HCV guidance: recommendations for testing, managing, and treating hepatitis C. American Association for the Study of Liver Disease, Infectious Disease Society of America. Available at: www.hcvguidelines.org (2017, accessed 7 June 2017)."},{"key":"bibr7-1078155217734626","first-page":"1057","volume":"19","author":"Eklung JW","year":"2005","journal-title":"Oncology (Williston Park)"},{"key":"bibr8-1078155217734626","unstructured":"\u201cWhen and in whom to initiate HCV therapy.\u201d HCV guidance: recommendations for testing, managing, and treating hepatitis C. American Association for the Study of Liver Disease, Infectious Disease Society of America. Available at: www.hcvguidelines.org (2016, accessed 7 August 2017)."},{"key":"bibr9-1078155217734626","doi-asserted-by":"publisher","DOI":"10.1177\/106002809202600311"},{"key":"bibr10-1078155217734626","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2015.983074"},{"key":"bibr11-1078155217734626","unstructured":"Docetaxel (package insert). Bridgewater, NJ: Sanofi-aventis US LLC, 2010."},{"key":"bibr12-1078155217734626","unstructured":"Paclitaxel (package insert). Princeton, NJ: Bristol-Meyers Squibb Company, 2011."},{"key":"bibr13-1078155217734626","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3283335277"},{"key":"bibr14-1078155217734626","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645030-00002"},{"key":"bibr15-1078155217734626","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3003-0"},{"key":"bibr16-1078155217734626","first-page":"2223","volume":"59","author":"Johnston DE","year":"1999","journal-title":"Am Fam Physician"},{"key":"bibr17-1078155217734626","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200607010-00004"},{"key":"bibr18-1078155217734626","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.4391"},{"key":"bibr19-1078155217734626","unstructured":"Carboplatin (package insert). Princeton, NJ: Bristol-Meyers Squibb Company, 2010."},{"key":"bibr20-1078155217734626","unstructured":"\u201cDrinking levels defined.\u201d National institute on alcohol abuse and alcoholism. Available at: https:\/\/www.niaaa.nih.gov\/alcohol-health\/overview-alcohol-consumption\/moderate-binge-drinking (accessed 7 August 2017)."},{"key":"bibr21-1078155217734626","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.153"},{"key":"bibr22-1078155217734626","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djg036"},{"key":"bibr23-1078155217734626","unstructured":"Gemcitabine. LiverTox, clinical and research information on drug-induced liver injury. National Institute of Health, US Department of Health & Human Services. Available at: http:\/\/livertox.nih.gov (2017, accessed 7 June 2017)."},{"key":"bibr24-1078155217734626","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.14.2780"},{"key":"bibr25-1078155217734626","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.12.029"},{"key":"bibr26-1078155217734626","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3068"},{"key":"bibr27-1078155217734626","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113216"},{"key":"bibr28-1078155217734626","first-page":"200","volume":"3","author":"Jain A","year":"2012","journal-title":"J Pharmacol Pharmacother"},{"key":"bibr29-1078155217734626","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp458"},{"key":"bibr30-1078155217734626","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.07.033"},{"key":"bibr31-1078155217734626","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2009.n.009"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155217734626","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155217734626","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155217734626","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:17:44Z","timestamp":1777688264000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155217734626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,11]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1177\/1078155217734626"],"URL":"https:\/\/doi.org\/10.1177\/1078155217734626","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,11]]}}}